Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients

Cancer Immunology, Immunotherapy

Volumn 51, Issue 10, 2002, Pages 532-538

  Labarrière, Nathalie ^a,c   Pandolfino, Marie Christine ^b,c   Gervois, Nadine ^a,c   Khammari, Amir ^b,c   Tessier, Marie Hélène ^b,c   Dréno, Brigitte ^a,c   Jotereau, Francine ^a,c  

^a INSERM   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE NANTES   (France)

Author keywords

Adoptive therapy; IFN ; Melanoma; T lymphocyte; TIL

Indexed keywords

INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; HUMAN; HUMAN CELL; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MELANOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE;

ADJUVANTS, IMMUNOLOGIC; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INJECTIONS; INTERLEUKIN-2; LYMPHATIC METASTASIS; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; T-LYMPHOCYTES;

EID: 0036032173     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-002-0313-3     Document Type: Article

References (28)

1. Aruga A, Shu S, Chang AE (1995) Tumor-specific granulocyte/macrophage colony-stimulating factor and interferon-gamma secretion is associated with in vivo therapeutic efficacy of activated tumor-draining lymph node cells. Cancer Immunol Immunother 41:317
2. + tumor-infiltrating lymphocytes. J Exp Med 173:647
3. Becker C, Pohla H, Frankenberger B, Schuler T, Assenmacher M, Schendel DJ, Blankenstein T (2001) Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay. Nat Med 7:1159
4. Benlalam H, Labarrière N, Linard B, Derre L, Diez E, Pandolfino MC, Bonneville M, Jotereau F (2001) Comprehensive analysis of the frequency of recognition of melanoma associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): Implications for immunotherapy. Eur J Immunol 31:2007
5. Dillman RO, Oldham RK, Barth NM, Cohen RJ, Minor DR, Birch R, Yannelli JR, Maleckar JR, Sferruzza A, Arnold J (1991) Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trial. Cancer 68:1
6. Fonteneau JF, Le Drean E, Le Guiner S, Gervois N, Diez E, Jotereau F (1997) Heterogeneity of biologic responses of melanoma-specific CTL. J Immunol 159:2831
7. Goedegebuure PS, Douville LM, Li H, Richmond GC, Schoof DD, Scavone M, Eberlein TJ (1995) Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: A pilot study. J Clin Oncol 13:1939
8. Granziero L, Krajewski S, Farness P, Yuan L, Courtney MK, Jackson MR, Peterson PA, Vitiello A (1999) Adoptive immunotherapy prevents prostate cancer in a transgenic animal model. Eur J Immunol 29:1127
9. Greenberg PD (1991) Adoptive T cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 49:281
10. + T cell adoptive immunotherapy. Immunity 13:265
11. Heslop HE, Ng CY, Li C, Smith CA, Loftin SK, Krance RA, Brenner MK, Rooney CM (1996) Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 2:551
12. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H (1998) The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 188:2357
13. + T cells. J Exp Med 186:757
14. Jotereau F, Pandolfino MC, Boudart D, Diez E, Dreno B, Douillard JY, Muller JY, Le Mevel B (1991) High-fold expansion of human cytotoxic T-lymphocytes specific for autologous melanoma cells for use in immunotherapy. J Immunother 10:405
15. Jung T, Schauer U, Heusser C, Neumann C, Rieger C (1993) Detection of intracellular cytokines by flow cytometry. J Immunol Methods 159:197
16. Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, Robbins PF, Sette A, Appella E, Rosenberg SA (1995) Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 154:3961
17. + CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL. J Immunol 163:184
18. Mitsuma S, Yoshizawa H, Ito K, Moriyama H, Wakabayashi M, Chou T, Arakawa M, Shu S (1994) Adoptive immunotherapy mediated by anti-TCR/IL-2-activated tumour-draining lymph node cells. Immunology 83:45
19. Mumberg D, Monach PA, Wanderling S, Philip M, Toledano AY, Schreiber RD, Schreiber H (1999) CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma [erratum appears in Proc Natl Acad Sci USA 2000; 97(5):2397]. Proc Natl Acad Sci USA 96:8633
20. Pandolfino MC, Labarriere N, Tessier MH, Cassidanius A, Bercegeay S, Lemarre P, Dehaut F, Dreno B, Jotereau F (2001) High-scale expansion of melanoma reactive TIL by a polyclonal stimulus: Predictability and relation with disease advancement. Cancer Immunol Immunother 50:134
21. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report [comment]. New Engl J Med 319:1676
22. Rosenberg SA, Spiess P, Lafreniere R (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318
23. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber, DJ, Weber, JS, Parkinson, DR, Seipp, CA, Einhorn, JH, and White DE (1994) Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin-2 [comment]. J Natl Cancer Inst 86:1159
24. Roskrow MA, Suzuki N, Gan Y, Sixbey JW, Ng CY, Kimbrough S, Hudson M, Brenner MK, Heslop HE, Rooney CM (1998) Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood 91:2925
25. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD (2001) IFN-gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410:1107
26. Siegel CT, Schreiber K, Meredith SC, Beck-Engeser GB, Lancki DW, Lazarski CA, Fu YX, Rowley DA, Schreiber H (2000) Enhanced growth of primary tumors in cancer-prone mice after immunization against the mutant region of an inherited oncoprotein. J Exp Med 191:1945
27. Tessier MH, Pandolfino MC, Jotereau F, Boudart D, Litoux P, Dreno B (1996) Home therapy with autologous tumour-infiltrating lymphocytes and subcutaneous interleukin-2 in metastatic melanoma [letter]. Eur J Cancer 32A:735
28. Toes RE, Ossendorp F, Offringa R, Melief CJ (1999) CD4 T cells and their role in antitumor immune responses [comment]. J Exp Med 189:753